http://www.broadcastmed.com/ http://www.broadcastmed.com/cancer/1411/news/new-15-million-grant-to-dana-farber-scientists-supports-research-into-innovative-approaches-to-endometrial-cancer-treatment Physician-scientists at Dana-Farber Cancer Institute have received a five-year, $15 million Program Project Grant from the National Cancer Institute (NCI) for research in endometrial cancer, which arises in the inner lining of the uterus and strikes more than 68,000 women a year in the U.S. http://www.broadcastmed.com/cancer/1411/news/new-15-million-grant-to-dana-farber-scientists-supports-research-into-innovative-approaches-to-endometrial-cancer-treatment Sun, 05 May 2024 17:12:00 EST http://www.broadcastmed.com/cancer/1411/news/unraveling-the-menin-mystery-to-halt-cancer-growth The story of research in menin and its relation to cancer 鈥� from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents 鈥� weaves through Dana-Farber at every step. http://www.broadcastmed.com/cancer/1411/news/unraveling-the-menin-mystery-to-halt-cancer-growth Tue, 30 Apr 2024 16:31:00 EST http://www.broadcastmed.com/cancer/2190/news/cedars-sinai-cancer-s-blood-and-marrow-transplant-patients-experience-superior-outcomes Allogeneic transplants use blood stem cells from donors鈥� bone marrow to treat patients with blood and bone marrow diseases.聽The Cedars-Sinai team performs more than 40 such transplants each year. http://www.broadcastmed.com/cancer/2190/news/cedars-sinai-cancer-s-blood-and-marrow-transplant-patients-experience-superior-outcomes Mon, 22 Apr 2024 16:48:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-researchers-explore-ai-s-potential-roles-in-predicting-and-diagnosing-cancer In 2022 and 2023, you couldn't go a day without hearing about artificial intelligence (AI). Generative AI tools such as chatbots and art generators had become a central topic in everyday conversations. But AI in cancer has deeper roots. Twenty-five years before ChatGPT burst onto the scene, computers started playing a larger role in cancer diagnostics. In 1997, mammograms weren't even digital yet, but computers had started analyzing them. The tools, called expert systems, used hard-coded logic to read digital images of X-ray-based mammograms to look for signs of cancer. http://www.broadcastmed.com/cancer/1411/news/dana-farber-researchers-explore-ai-s-potential-roles-in-predicting-and-diagnosing-cancer Fri, 19 Apr 2024 15:54:00 EST http://www.broadcastmed.com/cancer/1411/news/ancient-dna-reveals-origin-of-racial/ethnic-disparity-in-a-childhood-cancer There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago. http://www.broadcastmed.com/cancer/1411/news/ancient-dna-reveals-origin-of-racial/ethnic-disparity-in-a-childhood-cancer Tue, 09 Apr 2024 16:34:00 EST http://www.broadcastmed.com/cancer/1411/news/breast-cancer-trial-aims-to-improve-treatment-for-men Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and聽CDK4/6 inhibitors.聽In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don鈥檛 support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading聽a clinical trial for men with breast cancer. http://www.broadcastmed.com/cancer/1411/news/breast-cancer-trial-aims-to-improve-treatment-for-men Tue, 09 Apr 2024 16:13:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-cancer-institute-launches-neuro-inclusive-oncology-care-and-empowerment-program Dana-Farber Cancer Institute launched the聽Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD). http://www.broadcastmed.com/cancer/1411/news/dana-farber-cancer-institute-launches-neuro-inclusive-oncology-care-and-empowerment-program Tue, 02 Apr 2024 17:22:00 EST http://www.broadcastmed.com/cancer/1411/news/gordon-j-freeman-phd-recognized-with-2024-aacr-cancer-research-institute-lloyd-j-old-award-in-cancer-immunology Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR). http://www.broadcastmed.com/cancer/1411/news/gordon-j-freeman-phd-recognized-with-2024-aacr-cancer-research-institute-lloyd-j-old-award-in-cancer-immunology Tue, 02 Apr 2024 09:00:00 EST http://www.broadcastmed.com/cancer/1411/news/bispecific-antibody-therapies-for-lymphoma Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own. http://www.broadcastmed.com/cancer/1411/news/bispecific-antibody-therapies-for-lymphoma Sun, 24 Mar 2024 17:37:00 EST http://www.broadcastmed.com/cancer/2190/news/pediatric-cancer-expert-explains-new-options-for-children-with-sarcomas Q&A With Cedars-Sinai Guerin Children鈥檚 Pediatric Hematologist-Oncologist Leo Mascarenhas, MD, MS http://www.broadcastmed.com/cancer/2190/news/pediatric-cancer-expert-explains-new-options-for-children-with-sarcomas Thu, 21 Mar 2024 17:37:00 EST http://www.broadcastmed.com/cancer/1590/news/mapping-a-path-to-clinical-trials-bringing-fox-chase-s-innovative-care-to-the-temple-community Clinical trials are among the most important resources when it comes to effectively treating challenging cases of cancer, but at Fox Chase Cancer Center, these trials encompass much more than just testing new drug candidates that may be more effective alternative treatments. http://www.broadcastmed.com/cancer/1590/news/mapping-a-path-to-clinical-trials-bringing-fox-chase-s-innovative-care-to-the-temple-community Wed, 13 Mar 2024 08:42:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-and-gustave-roussy-to-hold-third-transatlantic-exchange-annual-scientific-conference-dedicated-to-advancing-oncology-research-and-practice Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine. http://www.broadcastmed.com/cancer/1411/news/dana-farber-and-gustave-roussy-to-hold-third-transatlantic-exchange-annual-scientific-conference-dedicated-to-advancing-oncology-research-and-practice Mon, 11 Mar 2024 15:38:00 EST http://www.broadcastmed.com/cancer/1411/news/bcl2-inhibitors-what-s-the-latest-research BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of聽acute myeloid leukemia聽(AML) and聽chronic lymphocytic leukemia聽(CLL) in adults. http://www.broadcastmed.com/cancer/1411/news/bcl2-inhibitors-what-s-the-latest-research Mon, 11 Mar 2024 15:05:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-cancer-institute-researchers-join-global-cancer-grand-challenges-team-taking-on-solid-tumors-in-children Dana-Farber Cancer Institute's聽Scott Armstrong, MD, PhD,聽Benjamin Ebert, MD, PhD,聽Eric Fischer, PhD,聽Cigall Kadoch, PhD, and聽Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children. http://www.broadcastmed.com/cancer/1411/news/dana-farber-cancer-institute-researchers-join-global-cancer-grand-challenges-team-taking-on-solid-tumors-in-children Mon, 11 Mar 2024 14:26:00 EST http://www.broadcastmed.com/cancer/8161/news/physician-survey-shows-lack-of-understanding-of-the-fda-s-approval-process Many physicians are unfamiliar with how the Food and Drug Administration鈥檚 (FDA) regulates new drugs and medical devices, and they may be under the impression that the data supporting these approvals are more rigorous than they are, according to a national survey of physicians conducted by researchers at UC San Francisco (UCSF).聽 http://www.broadcastmed.com/cancer/8161/news/physician-survey-shows-lack-of-understanding-of-the-fda-s-approval-process Fri, 01 Mar 2024 09:00:00 EST http://www.broadcastmed.com/cancer/1590/news/fox-chase-fellows-winter-2024 People say you never really leave Fox Chase. Just ask Matt Zibelman, MD, who was a Fox Chase hematology/oncology fellow and now is the GU Service Line Director of Clinical and Translational Research鈥攐r his colleague Mark Hallman, MD, PhD, a former Fox Chase Radiation Oncology resident, now serving as the GU Service Line Clinical Director http://www.broadcastmed.com/cancer/1590/news/fox-chase-fellows-winter-2024 Thu, 29 Feb 2024 13:06:00 EST http://www.broadcastmed.com/cancer/1590/news/many-legacies-to-carry-on In May 2023, Michael O. Meyers, MD, a surgical oncologist at UNC, was named the James F. and Alice B. Newsome Distinguished Professor. http://www.broadcastmed.com/cancer/1590/news/many-legacies-to-carry-on Thu, 29 Feb 2024 11:18:00 EST http://www.broadcastmed.com/cancer/1411/news/laurie-h-glimcher-md-selected-for-stat-s-2024-status-list Laurie H. Glimcher, MD,聽president and CEO of Dana-Farber Cancer Institute, is named to STAT's聽2024 STATUS List,聽featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech. http://www.broadcastmed.com/cancer/1411/news/laurie-h-glimcher-md-selected-for-stat-s-2024-status-list Wed, 28 Feb 2024 12:09:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-researchers-receive-aacr-2024-scientific-achievement-awards Christopher D.M. Fletcher, MD,聽Timothy R. Rebbeck, PhD,聽David Pellman, MD,聽and聽Gordon J. Freeman, PhD,聽will be recognized by the American Association for Cancer Research (AACR) with 2024 Scientific Achievement Awards. http://www.broadcastmed.com/cancer/1411/news/dana-farber-researchers-receive-aacr-2024-scientific-achievement-awards Tue, 27 Feb 2024 12:15:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-ceo-laurie-glimcher-has-always-been-a-trail-blazer-and-a-risk-taker Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks. http://www.broadcastmed.com/cancer/1411/news/dana-farber-ceo-laurie-glimcher-has-always-been-a-trail-blazer-and-a-risk-taker Tue, 27 Feb 2024 10:35:00 EST http://www.broadcastmed.com/cancer/1411/news/antibody-drug-conjugates-a-cancer-therapy-revolution Dana-Farber researchers explore how a novel therapy may benefit patients http://www.broadcastmed.com/cancer/1411/news/antibody-drug-conjugates-a-cancer-therapy-revolution Mon, 26 Feb 2024 10:19:00 EST http://www.broadcastmed.com/cancer/5225/news/preserving-laryngeal-structure-and-function-for-patients-with-cancer Johns Hopkins experts offer innovative surgical techniques that may lessen the damaging impact on the voices of patients with laryngeal cancer. http://www.broadcastmed.com/cancer/5225/news/preserving-laryngeal-structure-and-function-for-patients-with-cancer Fri, 23 Feb 2024 10:22:00 EST http://www.broadcastmed.com/cancer/1593/news/how-to-improve-survival-for-pediatric-leukemia-patients UCSF studies uncover effects of pre-conception smoking and racial disparities in pediatric leukemias http://www.broadcastmed.com/cancer/1593/news/how-to-improve-survival-for-pediatric-leukemia-patients Wed, 21 Feb 2024 09:28:00 EST http://www.broadcastmed.com/cancer/8161/news/radioligand-therapy-plus-pembrolizumab-may-benefit-patients-with-advanced-prostate-cancer Immune checkpoint inhibitors have demonstrated limited efficacy in treating prostate cancer. Efforts to improve outcomes with combination therapies have mostly failed to demonstrate improvements compared to other types of cancer. http://www.broadcastmed.com/cancer/8161/news/radioligand-therapy-plus-pembrolizumab-may-benefit-patients-with-advanced-prostate-cancer Mon, 19 Feb 2024 08:00:00 EST http://www.broadcastmed.com/cancer/9753/news/roswell-park-comprehensive-cancer-center-generate-biomedicines-enter-into-collaboration-agreement-to-accelerate-novel-cell-therapies-for-oncology-using-generative-ai Multi-year collaboration will enable development of complex, cutting-edge cell therapies and armoring technologies for solid tumor targets http://www.broadcastmed.com/cancer/9753/news/roswell-park-comprehensive-cancer-center-generate-biomedicines-enter-into-collaboration-agreement-to-accelerate-novel-cell-therapies-for-oncology-using-generative-ai Sun, 18 Feb 2024 14:25:00 EST http://www.broadcastmed.com/cancer/1590/news/inspiring-residents-to-climb-higher When asked why he chose Fox Chase Cancer Center for his urologic surgery fellowship (2019-2021), Marshall Strother, MD, responds, 鈥淚 liked the way 鈥楩ox,鈥� as he calls Fox Chase, has an exacting, intentional, and deliberate method of training. Hierarchies are flattened there, allowing new surgeons to work and learn with the most experienced on the team.鈥� http://www.broadcastmed.com/cancer/1590/news/inspiring-residents-to-climb-higher Wed, 14 Feb 2024 13:00:00 EST http://www.broadcastmed.com/cancer/2190/news/cedars-sinai-cancer-releases-2024-annual-report The 2024 Cedars-Sinai Cancer Annual Report is now accessible. By harnessing the collective expertise of top cancer researchers and leveraging leading-edge Al technology, Cedars-Sinai Cancer is transforming cancer research and patient care through improved screening, innovative treatments and community outreach initiatives. http://www.broadcastmed.com/cancer/2190/news/cedars-sinai-cancer-releases-2024-annual-report Wed, 14 Feb 2024 09:33:00 EST http://www.broadcastmed.com/cancer/1411/news/immunotherapy-for-cancer-what-it-is-how-it-works-and-where-it-s-going Immunotherapy refers to treatments that use the body鈥檚 immune system to combat diseases. Immuno-oncology focuses on efforts to use the immune system as a weapon against cancer.聽The immune system is a collection of organs, tissues, specialized cells, and substances that protect the body against infection and disease. While the immune system can often handle very small tumors on its own, either by destroying them or keeping them from growing, it can sometimes fail 鈥� either because a tumor grows too large, the cancer cells are too well camouflaged, or the tumor cells are able to stave off an immune system attack.聽A聽key discovery, made by Dana-Farber鈥檚 Gordon Freeman, PhD, and others, was that the immune system鈥檚 attack on cancer often falls short because many cancer cells display proteins, called immune checkpoint proteins, that bring the attack to a halt. http://www.broadcastmed.com/cancer/1411/news/immunotherapy-for-cancer-what-it-is-how-it-works-and-where-it-s-going Mon, 12 Feb 2024 14:33:00 EST http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-leads-first-in-world-brain-metastasis-trial Baptist Health Miami Cancer Institute聽is leading a groundbreaking聽clinical trial聽that is studying the use of a new medication combined with stereotactic radiosurgery to combat metastatic brain cancer. http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-leads-first-in-world-brain-metastasis-trial Mon, 12 Feb 2024 10:13:00 EST http://www.broadcastmed.com/cancer/1590/news/national-and-international-accolades Meet the bold clinicians and researchers whose work and perseverance push the edge of discovery, and have helped Fox Chase Cancer Center reach our 50th anniversary of excellence in cancer care. http://www.broadcastmed.com/cancer/1590/news/national-and-international-accolades Thu, 08 Feb 2024 11:13:00 EST http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-publication-analyzes-role-of-tissue-agnostic-therapies-for-the-treatment-of-primary-brain-tumors Researchers from Miami Cancer Institute, part of Baptist Health South Florida, recently published a study in聽Trends in Cancer聽that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The publication describes the current and potential impact of tissue-agnostic therapies on the management of PBTs. As part of the publication, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs in the context of challenges in managing these tumors. They also describe additional tissue-agnostic targets that hold promise for benefiting patients with PBTs. http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-publication-analyzes-role-of-tissue-agnostic-therapies-for-the-treatment-of-primary-brain-tumors Tue, 06 Feb 2024 10:26:00 EST http://www.broadcastmed.com/cancer/8161/news/study-finds-significant-chemical-exposures-in-women-with-cancer In a sign that exposure to certain endocrine-disrupting chemicals may be playing a role in cancers of the breast, ovary, skin and uterus, researchers have found that people who developed those cancers have significantly higher levels of these chemicals in their bodies. http://www.broadcastmed.com/cancer/8161/news/study-finds-significant-chemical-exposures-in-women-with-cancer Mon, 05 Feb 2024 09:00:00 EST http://www.broadcastmed.com/cancer/1106/news/advanced-prostate-cancer-genetic-testing-an-invaluable-tool A study led by Baptist Health Miami Cancer Institute shows that patients with TP53, RB1 and PTEN mutated prostate cancer have a lower overall survival rate than patients who are biomarker negative. The results emphasize the importance of genetic testing for all advanced cancer patients, the researchers say. http://www.broadcastmed.com/cancer/1106/news/advanced-prostate-cancer-genetic-testing-an-invaluable-tool Tue, 30 Jan 2024 10:51:00 EST http://www.broadcastmed.com/cancer/9753/news/clinical-trial-evaluates-triple-drug-regimen-for-patients-newly-diagnosed-with-flt3-mutated-aml Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. To complicate matters, often they are ineligible for intensive induction chemotherapy due to advanced age or overall poor health. But previous studies have shown that FLT3 inhibitors can extend survival in these patients, especially when administered in combination with other therapies. A clinical trial underway at Roswell Park Comprehensive Cancer Center is evaluating that strategy with the FLT3 inhibitor gilteritinib (brand name Xospata), combining it with the BCL-2 inhibitor venetoclax (brand names Venclexta, Venclyxto) and the low-dose chemotherapy drug azacitidine (brand names Vidaza, Onureg). http://www.broadcastmed.com/cancer/9753/news/clinical-trial-evaluates-triple-drug-regimen-for-patients-newly-diagnosed-with-flt3-mutated-aml Tue, 30 Jan 2024 09:56:00 EST http://www.broadcastmed.com/cancer/9753/news/simple-blood-protein-tests-predict-which-lymphoma-patients-are-most-likely-to-have-poor-car-t-outcomes International research team develops, validates approach for assessing and responding to elevated risk http://www.broadcastmed.com/cancer/9753/news/simple-blood-protein-tests-predict-which-lymphoma-patients-are-most-likely-to-have-poor-car-t-outcomes Tue, 30 Jan 2024 09:33:00 EST http://www.broadcastmed.com/cancer/8161/news/inclusion-of-new-risk-factors-can-improve-prediction-of-invasive-breast-cancer UCSF researchers update Breast Cancer Surveillance Consortium model to account for BMI and other familial risk factors. http://www.broadcastmed.com/cancer/8161/news/inclusion-of-new-risk-factors-can-improve-prediction-of-invasive-breast-cancer Tue, 30 Jan 2024 09:00:00 EST http://www.broadcastmed.com/cancer/1411/news/melanoma-vaccine-progress-and-possibility A melanoma therapeutic vaccine is a type of聽personalized cancer vaccine聽that is intended to train the immune system to fight cancer cells in a way that lasts many years. These novel vaccines are personally tailored to recognize the mutations present in an individual鈥檚 tumor cells. They are different from vaccines for infectious diseases, which are typically given to as many people as possible in a community to prevent a virus from spreading.聽Currently, no personalized melanoma vaccines are approved medicines, though several have been tested in clinical trials. A personalized RNA vaccine has recently shown promising data in patients with high-risk melanoma.聽聽 http://www.broadcastmed.com/cancer/1411/news/melanoma-vaccine-progress-and-possibility Sun, 28 Jan 2024 19:05:00 EST http://www.broadcastmed.com/cancer/1411/news/immunotherapy-post-surgery-improves-overall-survival-for-kidney-cancer For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo. http://www.broadcastmed.com/cancer/1411/news/immunotherapy-post-surgery-improves-overall-survival-for-kidney-cancer Sun, 28 Jan 2024 18:55:00 EST http://www.broadcastmed.com/neurology/8161/news/focused-ultrasound-technology-may-overcome-barrier-to-brain-tumor-treatments The blood-brain barrier protects the brain from many viruses, bacteria, and other harmful small molecules that could be circulating throughout the body. However, this same barrier prevents many cancer therapies from reaching brain tumors. http://www.broadcastmed.com/neurology/8161/news/focused-ultrasound-technology-may-overcome-barrier-to-brain-tumor-treatments Fri, 26 Jan 2024 09:00:00 EST http://www.broadcastmed.com/cancer/8161/news/ucsf-cancer-researcher-thomas-martin-receives-4-6-million-cirm-grant UC San Francisco鈥檚 Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.聽 http://www.broadcastmed.com/cancer/8161/news/ucsf-cancer-researcher-thomas-martin-receives-4-6-million-cirm-grant Tue, 23 Jan 2024 09:00:00 EST http://www.broadcastmed.com/urology/1590/news/benign-prostatic-hyperplasia With one of the largest and most experienced urology teams in the region and the latest treatment capabilities, the Fox Chase-Temple Urologic Institute is a trusted leader in treating all types of urologic conditions. http://www.broadcastmed.com/urology/1590/news/benign-prostatic-hyperplasia Fri, 19 Jan 2024 10:29:00 EST http://www.broadcastmed.com/cancer/3593/news/when-halting-myelofibrosis-progression-fails-try-changing-its-course-instead The decades-long research efforts of a consortium, led by Mount Sinai researchers, to deplete myelofibrosis stem cells altogether鈥攊nstead of merely stopping proliferation鈥攈as received renewed funding. http://www.broadcastmed.com/cancer/3593/news/when-halting-myelofibrosis-progression-fails-try-changing-its-course-instead Thu, 11 Jan 2024 11:30:00 EST http://www.broadcastmed.com/cancer/3593/news/the-different-face-of-liver-cancer-in-underserved-minority-populations African Americans are less likely to have cirrhosis at the time of liver cancer diagnosis, but are more likely to have larger tumors. http://www.broadcastmed.com/cancer/3593/news/the-different-face-of-liver-cancer-in-underserved-minority-populations Thu, 11 Jan 2024 11:23:00 EST http://www.broadcastmed.com/cancer/5225/news/pediatric-brain-cancer-julian-s-story When 3-week-old Julian Letchworth arrived at聽Johns Hopkins Children鈥檚 Center鈥檚聽emergency department on a Saturday in August, his prognosis was beyond dire. Emergency brain surgery might save his life 鈥� temporarily 鈥� if he survived the procedure. http://www.broadcastmed.com/cancer/5225/news/pediatric-brain-cancer-julian-s-story Wed, 10 Jan 2024 08:40:00 EST http://www.broadcastmed.com/cancer/9753/news/clinical-trial-builds-on-prior-promising-results-of-iberdomide-in-patients-with-relapsed/refractory-multiple-myeloma Because most multiple myeloma patients are 65 or older, including some who are frail, successive lines of therapy to address relapsed disease often take their toll 鈥� so keeping patients in deep remission after frontline treatment is highly desirable. http://www.broadcastmed.com/cancer/9753/news/clinical-trial-builds-on-prior-promising-results-of-iberdomide-in-patients-with-relapsed/refractory-multiple-myeloma Mon, 08 Jan 2024 09:48:00 EST http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-to-host-fifth-global-summit-on-immunotherapies-for-hematologic-malignancies Miami Cancer Institute, part of Baptist Health South Florida, announced it will host the Fifth Annual Global Summit on Immunotherapies for Hematologic Malignancies, to be held March 8-9, 2024, at the JW Marriott Hotel in Brickell, Miami, Fla. http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-to-host-fifth-global-summit-on-immunotherapies-for-hematologic-malignancies Wed, 03 Jan 2024 16:40:00 EST http://www.broadcastmed.com/cancer/1411/news/psilocybin-eases-depression-in-patients-with-cancer-study-finds For patients with cancer who are suffering from major depression, treatment with psilocybin plus individual and group psychological support can significantly relieve depressive symptoms, a clinical trial has found. In a companion study led by Dana-Farber Cancer Institute investigators, trial participants said the treatment experience with psilocybin 鈥� a hallucinogenic compound derived from certain mushrooms 鈥� created a sense of connection, meaning, and transcendence that aided the healing process. http://www.broadcastmed.com/cancer/1411/news/psilocybin-eases-depression-in-patients-with-cancer-study-finds Mon, 01 Jan 2024 18:20:00 EST http://www.broadcastmed.com/cancer/1411/news/exploring-how-car-t-cell-therapy-may-help-more-patients CAR T-cell therapy聽burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of聽immune effector cell (IEC) therapy, typically a patient's own immune cells 鈥� known as T cells 鈥� are genetically re-engineered to identify and kill cancer cells. http://www.broadcastmed.com/cancer/1411/news/exploring-how-car-t-cell-therapy-may-help-more-patients Mon, 01 Jan 2024 17:46:00 EST http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-achieves-aahrpp-accreditation The Association for Accreditation of Human Research Protection Programs has recognized Miami Cancer Institute for promoting ethically sound and safe human subject research practices. http://www.broadcastmed.com/cancer/1106/news/miami-cancer-institute-achieves-aahrpp-accreditation Wed, 20 Dec 2023 10:43:00 EST http://www.broadcastmed.com/cancer/1106/news/novel-artificial-intelligence-technology-shows-promising-results-for-earlier-and-more-accurate-breast-cancer-detection Data from the Centers for Disease Control and Prevention highlight that Breast Cancer is second most common form of cancer among women in the U.S. with approximately 240,000 new breast cancer diagnoses each year. http://www.broadcastmed.com/cancer/1106/news/novel-artificial-intelligence-technology-shows-promising-results-for-earlier-and-more-accurate-breast-cancer-detection Wed, 20 Dec 2023 10:34:00 EST